Cancer News and Research

Latest Cancer News and Research

FDA provides PMA approval for Spectrascience's WavSTAT technology enhancements

SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that its application for premarket approval (PMA) relating to key enhancements of its WavSTAT platform technology has been approved by the Food and Drug Administration. The Company can now begin commercial distribution of the enhanced WavSTAT technology.

17 Sep 2009

Melbourne's national approach for managing chronic pain

An unprecedented gathering of some of Australia's leading authorities in pain medicine, together with consumer groups representing chronic pain sufferers, will meet in Melbourne today to work towards a national, coordinated approach to managing chronic pain.

17 Sep 2009

Expo East 2009 conference to focus on integrative cancer care model

People diagnosed with cancer have a number of treatment options to choose from and increasingly, alternative and complementary therapies such as yoga, meditation, healing touch, music therapy, and nutritional supplementation are among them.

17 Sep 2009

ColoMarker assay achieves 100 percent detection rate for colon cancers

Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials.

17 Sep 2009

Multi-detector row computed tomography predicts malignancy of IPMNs

A clinical research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses the role of multi-detector row computed tomography (MDCT) in predicting malignancy of IPMNs preoperatively. The research team led by Prof. Wang DB from Ruijin Hospital of Shanghai Jiao Tong University School of Medicine recruited a total of 20 patients with pathologically-confirmed IPMNs in their study. Axial MDCT images combined with CT angiography (CTA) and multiplanar volume or curved reformations (MPVR or CR) were preoperatively acquired.

17 Sep 2009

Educational events for physicians who diagnose and treat prostate cancer

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a series of educational events designed for radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians who diagnose and treat patients with prostate cancer.

17 Sep 2009

Study: Therapy addition reduces risk of stroke and other cardiovascular events

Data from the independent KYOTO HEART study, presented recently at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published online in the European Heart Journal demonstrated the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events(1) including stroke, compared to conventional non-ARB treatment regimen.(1)

17 Sep 2009

Researchers investigate individual's ability to get rid of Hepatitis C

More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.

17 Sep 2009

Protein kinase Erk3 plays a critical role in intrauterine growth and lung maturation

Dr. Sylvain Meloche, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and his colleagues have uncovered the critical role played by the protein kinase Erk3 in fetal growth potential and lung maturation.

17 Sep 2009

Cellzome's quantitative chemical proteomics platform described in a journal

Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling" is now available online in Nature.

17 Sep 2009

GENova to sign extensive collaboration agreement with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it is in final negotiations with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments for an extensive collaboration agreement.

17 Sep 2009

Leading doctors call for climate change action to prevent 'global health catastrophe'

On Wednesday, the British Medical Journal (BMJ) and the Lancet simultaneously published an editorial (available here and here) and an accompanying letter (here and here) from 18 doctor association leaders to highlight the need for action at a December U.N. conference on climate change in Copenhagen, Reuters reports (Doyle, 9/16).

17 Sep 2009

Standard liver volume formula for Chinese adults published

Living donor liver transplantation (LDLT) has been used to alleviate the shortage of available liver donors. Accurate estimation of the standard liver volume (SLV) of the living donor and recipient is crucial. Scholars of different countries established several SLV formulae from clinical data, but which formula was the most accurate for Chinese adults has remained unclear.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Green tea may help prevent cancer and bone loss

Researchers in Hong Kong are reporting new evidence that green tea - one of the most popular beverages consumed worldwide and now available as a dietary supplement - may help improve bone health.

17 Sep 2009

Avaxia Biologics receives NIH grant to develop an antibody therapeutic for oral mucositis

Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis.

17 Sep 2009

Wireless sensor being studied at the Virginia Commonwealth University Medical Center

A wireless, credit-card-sized sensor that can detect whether health care workers have properly washed their hands upon entering a patient's room is being studied at the Virginia Commonwealth University Medical Center. The device could greatly reduce the number of hospital acquired infections nationwide since most are transmitted through contact due to poor hand-washing practice.

17 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

16 Sep 2009